

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6008311

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FL THERAPEUTICS LLC	09/28/2017
RECEIVING PARTY DATA	
Name:	ZHUHAI BEIHAI BIOTECH CO., LTD.
Street Address:	3F, BLG 2, NO. 6366 ZHUHAI AVE., JINWAN,
City:	ZHUHAI
State/Country:	CHINA
Postal Code:	519085
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16669152
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 368-2119
Email:	krahler@fr.com, apsi@fr.com
Correspondent Name:	VASILY A. IGNATENKO
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	45748-0002002
NAME OF SUBMITTER:	NIKKI KRAHLER
SIGNATURE:	/Nikki Krahler/
DATE SIGNED:	03/11/2020
Total Attachments: 6	
source=45748-0002002_Assignment_FLtoZhuhai#page1.tif	
source=45748-0002002_Assignment_FLtoZhuhai#page2.tif	
source=45748-0002002_Assignment_FLtoZhuhai#page3.tif	
source=45748-0002002_Assignment_FLtoZhuhai#page4.tif	
source=45748-0002002_Assignment_FLtoZhuhai#page5.tif	

Assignment from FL Therapeutics LLC to Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

ASSIGNMENT

Assignor: FL Therapeutics LLC
 a limited liability company organized and existing under the laws of New Jersey,
 and having a place of business at:
 174 Nassau Street, Suite 1100
 Princeton, NJ 08542

Assignee: Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)
 a limited liability company organized and existing under the laws of
 China, and having a place of business at:
 A6, 4F, No 10 Technology 1st Road
 Gangwan Ave., Tangjia Bay Town
 Zhuhai, China

Matter ID	Country	Application No.	Filing Date	Title
39201-0002US1	United States	13/498,641	3/28/2012	Compounds as TRPV1 Antagonists, Pharmaceutical Compositions and Medical Uses Thereof
39201-0003001	United States	14/076,310	11/11/2013	NOVEL ANALOGS OF CAMPTOTHECIN
39201-0003P01	United States	61/725,778	11/13/2012	NOVEL ANALOGS OF CAMPTOTHECIN
39201-0003P02	United States	61/762,388	2/8/2013	NOVEL ANALOGS OF CAMPTOTHECIN
39201-0004P01	United States	61/760,573	2/4/2013	SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN
39201-0004US1	United States	14/765,773	8/4/2015	SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN
39201-0004WO1	WIPO	PCT/US2014/014079	1/31/2014	SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN
39201-0006P01	United States	62/018,236	6/27/2014	ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0006P02	United States	62/046,616	9/5/2014	ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0006US1	United States	15/320,353	12/20/2016	ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0006WO1	WIPO	PCT/US2015/038077	6/26/2015	ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0007P01	United States	62/068,573	10/24/2014	3-SUBSTITUTED PIPERIDINE-2, 6-DIONES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0007US1	United States	15/520,770	4/20/2017	3-SUBSTITUTED PIPERIDINE-2, 6-DIONES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0007WO1	WIPO	PCT/US2015/056900	10/22/2015	3-SUBSTITUTED PIPERIDINE-2,

OS:

Assignment from FL Therapeutics LLC to Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

				6-DIONES AND NON-COVALENT COMPLEXES WITH ALBUMIN
39201-0008P01	United States	62/162,545	5/15/2015	DOCETAXEL AND HUMAN SERUM ALBUMIN COMPLEXES
39201-0008P02	United States	62/198,784	7/30/2015	HUMAN SERUM ALBUMIN COMPLEXES
39201-0008P03	United States	62/209,053	8/24/2015	DOCETAXEL AND HUMAN SERUM ALBUMIN COMPLEXES
39201-0008P04	United States	62/221,205	9/21/2015	HUMAN SERUM ALBUMIN COMPLEXES
39201-0008P05	United States	62/299,209	2/24/2016	DOCETAXEL AND HUMAN SERUM ALBUMIN COMPLEXES
39201-0008WO1	WIPO	PCT/US2016/032760	5/16/2016	DOCETAXEL AND HUMAN SERUM ALBUMIN COMPLEXES
39201-0009P01	United States	62/279,074	1/15/2016	COMPOSITIONS AND FORMULATIONS INCLUDING CABAZITAXEL AND HUMAN SERUM ALBUMIN
39201-0009P02	United States	62/420,986	11/11/2016	COMPOSITIONS AND FORMULATIONS INCLUDING CABAZITAXEL AND HUMAN SERUM ALBUMIN
39201-0009WO1	WIPO	PCT/US2017/013194	1/12/2017	COMPOSITIONS AND FORMULATIONS INCLUDING CABAZITAXEL AND HUMAN SERUM ALBUMIN
39201-0010P01	United States	62/342,063	5/26/2016	FORMULATIONS OF CHLORAMBUCIL
39201-0010P02	United States	62/506,067	5/15/2017	FORMULATIONS OF CHLORAMBUCIL
39201-0010WO1	WIPO	PCT/US2017/034407	5/25/2017	FORMULATIONS OF CHLORAMBUCIL
39201-0013P01	United States	62/730,453 62/370,453 <i>Q.S.</i>	8/3/2016	FORMULATIONS OF FOSAPREPITANT AND APREPITANT
39201-0013P02	United States	62/412,085	10/24/2016	FORMULATIONS OF FOSAPREPITANT AND APREPITANT
39201-0013WO1	WIPO	PCT/US2017/045290	8/3/2017	FORMULATIONS OF FOSAPREPITANT AND APREPITANT
39201-0014P01	United States	62/377,333	8/19/2016	FORMULATIONS OF IBRUTINIB
39201-0014WO1	WIPO	PCT/US2017/047501	8/18/2017	FORMULATIONS OF IBRUTINIB
39201-0015P01	United States	62/393,506	9/12/2016	FORMULATIONS OF CABOZANTINIB
39201-0016P01	United States	62/424,805	11/21/2016	FORMULATIONS OF ROLAPITANT
39201-0017P01	United States	62/406,701	10/11/2016	ABIRATERONE DERIVATIVE AND FORMULATIONS THEREOF
39201-0018P01	United States	62/413,603	10/27/2016	NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN

Q.S.

Assignment from FL Therapeutics LLC to Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

39201-0018P02	United States	62-420,397	11/10/2016	NEUTRAL PH COMPOSITIONS OF DOCE TAXEL AND HUMAN SERUM ALBUMIN
39201-0020P01	United States	62-492,714	5/1/2017	FORMULATIONS AND COMPOSITIONS OF DOCE TAXEL

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in its own name wherever so permitted by law or in the name of Assignee wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.
3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.

Q.S.

Assignment from FL Therapeutics LLC to Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]



Assignment from FL Therapeutics LLC to Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

The Assignor hereby executes this Assignment.

Assignor: FL Therapeutics LLC

Signature: 

Date: 9/8/2017


Name: QUN SUN

Title: CEO

Witness:

Name: Haihua Jiang

Date: 9/8/2017

Signature: 

Name: JianPing Tang


Date: 9/8/2017

Signature: 

Assignment from FL Therapeutics LLC to Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: Zhuhai Beihai Biotech Co., Ltd. (珠海贝海生物技术有限公司)

Signature: 

Date: 9/8/2017


Name: QUN SUN

Title: CEO

Witness:

Name: Haihua Jiang

Date: 9/8/2017

Signature: 

Name: Jian Ping Tang

Date: 9/8/2017

Signature: 